verified SJR 1,674 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · BioScientifica Ltd.

workspace_premium Q1 — Oncology lock Subscription

Endocrine-Related Cancer

Endocrine-Related Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 149. It has an SJR impact factor of 1,674 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,674.

Endocrine-Related Cancer focuses its scope in these topics and keywords: breast, phosphorylation, serine, prostate, receptor, pheochromocytoma, factor, growth, impact, aspects, ...

ISSN: 1351-0088

Publisher: BioScientifica Ltd.

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,674 Q1

H-index 149

Acceptance rate pie_chart

22% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,674

H-index

149

Docs (year)

Docs 3y

287

Total refs

2547

Cites 3y

1197

Citable 3y

282

Cites/Doc 2y

4.47

Ref/Doc

39.18

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Association between changes in fat distribution and biomarkers for breast cancer

Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.

Cross-resistance to different aromatase inhibitors in breast cancer treatment.

Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes

Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.

Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.

Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.

Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.

Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.

Carcinoid case presentation and discussion: the American perspective.

Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis

BRCA1/2 carriers and endocrine risk modifiers.

SHOW MORE ARTICLES

BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors

A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas.

Aromatase within the breast.

Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary gla

Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.

Aromatase inhibitors and their use in the sequential setting.

Aromatase inhibitors and their antitumor effects in model systems.

Aromatase and its inhibitors: new biology and clinical perspectives.

Aggressive and malignant pituitary tumours: state-of-the-art

Advances in risk-oriented surgery for multiple endocrine neoplasia type 2

Ablative therapies for liver metastases of digestive endocrine tumours.

A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo

FAQs

Endocrine-Related Cancer has an SJR of 1,674 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Endocrine-Related Cancer is 22%.

Endocrine-Related Cancer

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Endocrine-Related Cancer?

What is the APC / publication cost?

What is the acceptance rate?